Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y, Iida K, Yutani C, Takahashi S, Chiba Y, Ohishi S, Mukai T
National Cardiovascular Center Research Institute, Osaka, Japan.
Hum Mol Genet. 1996 Jun;5(6):783-8. doi: 10.1093/hmg/5.6.783.
p57KIP2 is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. The gene encoding human p57KIP2 is located on chromosome 11p15.5, a region implicated in both sporadic cancers and Beckwith-Wiedemann syndrome (BWS), a cancer syndrome, making it a tumor suppressor candidate. Several types of childhood tumors including Wilms' tumor, adrenocortical carcinoma and rhabdomyosarcoma display a specific loss of maternal 11p15 alleles, suggesting that genomic imprinting plays an important part. Genetic analysis of the familial BWS has indicated maternal carriers and suggested a role in genomic imprinting. Previously, we demonstrated that p57KIP2 is imprinted in the mouse. Here we describe the genomic imprinting of human p57KIP2 and the reduction of its expression in Wilms' tumors. High resolution mapping locates p57KIP2 in the region responsible for both tumor suppressivity and BWS.
p57KIP2是几种G1细胞周期蛋白复合物的强效紧密结合抑制剂,是细胞增殖的负调节因子。编码人类p57KIP2的基因位于11号染色体p15.5区域,该区域与散发性癌症和贝克威思-维德曼综合征(BWS,一种癌症综合征)都有关联,这使其成为肿瘤抑制候选基因。包括肾母细胞瘤、肾上腺皮质癌和横纹肌肉瘤在内的几种儿童肿瘤显示出母源11p15等位基因的特异性缺失,这表明基因组印记起着重要作用。对家族性BWS的基因分析表明存在母源携带者,并提示其在基因组印记中的作用。此前,我们证明p57KIP2在小鼠中是印记基因。在此,我们描述人类p57KIP2的基因组印记及其在肾母细胞瘤中的表达降低。高分辨率定位将p57KIP2定位于负责肿瘤抑制和BWS的区域。